Skip to Content

Join the 'Immune Globulin Subcutaneous' group to help and get support from people like you.

Immune Globulin Subcutaneous News

FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Posted 20 Mar 2018 by Drugs.com

KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neu ...

'Immunotherapy' in Monkeys Shows Promise as Long-Term HIV Treatment

Posted 13 Mar 2017 by Drugs.com

MONDAY, March 13, 2017 – Lab experiments with monkeys suggest that "immunotherapy" holds promise as a long-term treatment for HIV, researchers say. Treatment with two anti-HIV antibodies right after infection might help keep the AIDS-causing virus in check for a prolonged period, according to the new study. Despite an arsenal of HIV drugs, effective long-term treatment remains elusive because ...

Health Tip: Could Allergy Shots Help You?

Posted 21 Feb 2017 by Drugs.com

-- If you have allergies, regular shots (immunotherapy) are designed to make you less sensitive to allergens over time. The American Academy of Allergy, Asthma and Immunology says you may be a candidate for allergy shots if: Your symptoms are moderate-to-severe and your allergy season lasts a few months or more. You want to avoid long-term use of allergy medications. You can commit the time ...

Immunotherapy Not a Quick Fix for Hay Fever

Posted 15 Feb 2017 by Drugs.com

TUESDAY, Feb. 14, 2017 – Immunotherapy – often in the form of allergy shots – can combat the runny nose, itchy eyes, congestion, sneezing and sinus pressure of persistent hay fever. But it can't be done in less than three years, British researchers report. Two years of immunotherapy was only as effective as a placebo, the study authors said. The key, the researchers added, seems to be a third ...

Shire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency

Posted 16 Sep 2016 by Drugs.com

Lexington, Mass. – September 14, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted approval for Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older. Cuvitru is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disor ...

Talecris Biotherapeutics Receives FDA Approval for Gamunex-C

Posted 17 Oct 2010 by Drugs.com

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ – Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the ...

CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy

Posted 10 Mar 2010 by Drugs.com

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Mar 4, 2010 - CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against ...

Ask a Question

Further Information

Related Condition Support Groups

Primary Immunodeficiency Syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Related Drug Support Groups

Hizentra, Vivaglobin, Cuvitru

Immune Globulin Subcutaneous Patient Information at Drugs.com